Yes.

I am sorry but it cannot be slowed, it will only speed up.

I would say the next few years.

Yes.

I second this, love me some Tony Seba.

Fantastic work, a major advance for AI.

Google's Flan-T5.

Cerebras just put up a 1 exaflop supercomputer in 3 days, so I would say it's possible.

Correct.

Yes. You can achieve a singularity through nanotechnology or genetic engineering, there are probably other ways as well.

Let us hope that doesn't happen.

The U-3 is flawed for many reasons and here is an article explaining some of them https://www.forbes.com/sites/greatspeculations/2012/10/16/why-jack-welch-has-a-point-about-unemployment-numbers/?sh=7708646b6554

As far as automation goes, I don't keep a treasure trove of links to articles or sources that I have gleaned info from. I can tell you that most of the companies that are automating are doing so quickly and quietly much like what Mcdonalds is doing with their drive through AI.

>Using a two-step phage-editing and enrichment method, we achieved seven markerless genome edits in three diverse phages with 100% efficiency, including edits as large as multi-gene deletions and as small as replacing a single codon. Cas13a can be applied as a generalizable tool for editing the most abundant and diverse biological entities on Earth.

We can now efficiently edit the genes of viruses that infect bacteria with the newer versions of CRISPR.

>For their influenza vaccine, the researchers created an mRNA cocktail encoding the four influenza proteins neuraminidase, nucleoprotein, matrix protein 2, and the stalk portion of hemagglutinin
>
>The vaccine was then injected into a group of twenty or so naive mice who had never experienced influenza before. They either got a quadrivalent jab (meaning all four mRNA segments for each protein was present) or monovalent (the conventional flu vaccine or vaccines containing an individual mRNA for any one of the proteins). Some animals received one shot, while others lucked out with one shot plus a booster four weeks later. The mice were then challenged with an assortment of different influenza strains, both that infect humans and other animals like dogs.
>
>“When we mix all of them together, we get the broadest immune response,” he says. “You get the engagement of T cells against the nucleoprotein, you get antibodies, and we get a pretty strong neuraminidase response. That’s kind of the beauty here that you’re flexible in what types of [viral proteins] you use… and you have a lot of possibilities to try [out].”
>
>The researchers also expect it wouldn’t need to undergo annual updates as our current ones do. Instead, they might last for a few years.

I do a lot of research into these topics and this is a guestimation based on what I currently know about the state of automation as a whole. I also prefer the U-6 unemployment numbers as they give a more complete picture.

We are going to need it this decade, probably within a few years.

>Two major studies published in Nature have uncovered a new level of control of cancer gene activity within tumors, termed cancer's "dark matter."
>
>The revelation shows that epigenetics, cells controlling gene activity, play a crucial role in the development of cancer. Cancers are usually tested for DNA mutations alone, which can miss this level of control, thereby failing to predict how cancers may behave and respond to treatment.

"A 16-people team — including an astronaut, a space-treaty drafter, a boxer, and several astrobiologists"

I felt like I was reading the synopsis of an anime.

>The CRISPR system, which involves a Cas enzyme to cut DNA, is a powerful tool for gene editing. But the genetic scissors sometimes make changes at the wrong place, creating a major safety problem that could limit their therapeutic use.
>
>Now, scientists at the University of Texas (UT) at Austin have refined the Cas9 protein used in the Nobel Prize-winning CRISPR-Cas9 tool. The new version, dubbed SuperFi-Cas9, was thousands of times less likely to perform off-target editing but just as efficient at on-target editing as the original version, the team said in a paper published in Nature.
>
>“This really could be a game-changer in terms of a wider application of the CRISPR-Cas systems in gene editing,” Kenneth Johnson, Ph.D., the study’s co-senior author, said in a statement.

>A second generation of Covid-19 mRNA vaccines is making its way onto the scene. Common to many of them is the use of self-amplifying RNA technology, which maximizes antigen expression. Now, researchers have developed a self-amplifying RNA vaccine with a number of exciting new characteristics. First, it doesn’t require any of the nucleobase modifications that conventional mRNA vaccines depend on for improved stability. Second, it simply uses “naked” RNA injected directly without a protective lipid nanoparticle. Third, the vaccine is designed to be administered into the outer layer of the skin —the dermis— for improved cellular immunity. And fourth, it has been optimized to suit the temperature range of the surface of the body, rather than the core of the body.